How to diagnose NAFLD in 2016

Journal of Hepatology

Volumn 65, Issue 3, 2016, Pages 643-644

  Bugianesi, E ^a   Rosso, C ^a   Cortez Pinto, H ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

Biomarkers; Biopsy; Fatty liver; Fibrosis; NAFLD; NASH; Screening; Steatosis

Indexed keywords

DISEASE SEVERITY; FOLLOW UP; HUMAN; LIVER BIOPSY; LIVER EXAMINATION; LIVER FIBROSIS; MEDICAL SPECIALIST; NONALCOHOLIC FATTY LIVER; NOTE; PATIENT REFERRAL; PRIORITY JOURNAL; RISK FACTOR; SCREENING TEST;

HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84991111392     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.05.038     Document Type: Note

References (8)

1. [1] European Association for the Study of the Liver (EASL) European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Electronic address: easloffice@easloffice.eu J Hepatol 64 (2016), 1388–1402.
2. [2] Fedchuk, L., Nascimbeni, F., Pais, R., Charlotte, F., Housset, C., Ratziu, V., Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 40 (2014), 1209–1222.
3. [3] Angulo, P., Kleiner, D.E., Dam-Larsen, S., Adams, L.A., Bjornsson, E.S., Charatcharoenwitthaya, P., et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology, 149, 2015 389–397 e310.
4. [4] Ekstedt, M., Hagstrom, H., Nasr, P., Fredrikson, M., Stal, P., Kechagias, S., et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61 (2015), 1547–1554.
5. [5] Angulo, P., Bugianesi, E., Bjornsson, E.S., Charatcharoenwitthaya, P., Mills, P.R., Barrera, F., et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 145 (2013), 782–789.
6. [6] Liu, Y.L., Patman, G.L., Leahart, J.B., Piquet, A.C., Burt, A.D., Dufour, J.F., et al. Carriage of the PNPLA3 rs 738409C>G confers an increased risk of of non-alcoholic associated hepatocellular carcinoma. J Hepatol 61 (2014), 75–81.
7. [7] Sanyal, A.J., Brunt, E.M., Kleiner, D.E., Kowdley, K.V., Chalasani, N., Lavine, J.E., et al. Endpoints for clinical trial design for Nonalcoholic steatohepatitis. Hepatology 54 (2011), 344–353.
8. [8] Bedossa, P., FLIP Pathology Consortium. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology 60 (2014), 565–575.